ERBB2 and breast cancer: McEvoy et al. performed cost-effectiveness analyses comparing observation versus SLNB in this particular subgroup of patients (postmenopausal patients with HR + /HER2- T1-T2cN0 BC) [30] and found that observation resulted in lower costs and higher QALYs in patients with N0 or N1 BC.